Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer

Karla Kerlikowske, Charlotte C. Gard, Jeffrey A. Tice, Elad Ziv, Steven R. Cummings, Diana L Miglioretti

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Risk factors may differentially influence development of estrogen receptor (ER)-positive vs -negative breast cancer. We examined associations with strong, prevalent risk factors by ER subtype. Methods: Of 1 279 443 women age 35 to 74 years participating in the Breast Cancer Surveillance Consortium, 14 969 developed ER-positive and 3617 developed ER-negative invasive breast cancer. We calculated hazard ratios (HRs) using Cox regression and compared ER subtype hazard ratios at representative ages or by menopausal status using Wald tests. All statistical tests were two-sided. Results: For women age 40 years, compared with no prior biopsy, ER-positive vs ER-negative HRs were 1.53 (95% CI = 1.30 to 1.81) vs 1.26 (95% CI = 0.90 to 1.76) for nonproliferative disease, 1.63 (95% CI = 1.23 to 2.17) vs 1.41 (95% CI = 0.78 to 2.57) for proliferative disease without atypia, and 4.47 (95% CI = 2.88 to 6.96) vs 0.20 (95% CI = 0.02 to 2.51) for proliferative disease with atypia. Benign disease proliferation risk was stronger for ER-positive than ER-negative cancer for women age 35 years (Wald P = .04), age 40 years (Wald P = .04), and age 50 years (Wald P = .06). Among pre/perimenopausal women, body mass index (BMI) had a stronger association with ER-negative than ER-positive cancer (obese II/III vs. normal weight: HR = 1.52, 95% CI = 1.19 to 1.94; vs 1.21, 95% CI = 1.08 to 1.36). Increasing BMI similarly increased ER-positive and ER-negative cancer risk among postmenopausal hormone users (Wald P = .15) and nonusers (Wald P = .08). Associations with ER subtype varied by race/ethnicity across all ages (P <. 001) and by family history of breast cancer and breast density for specific ages. Conclusions: Strength of risk factor associations differed by ER subtype. Separate risk models for ER subtypes may improve identification of women for targeted prevention strategies.

Original languageEnglish (US)
Article numberdjw276
JournalJournal of the National Cancer Institute
Volume109
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Estrogen Receptors
Breast Neoplasms
Body Mass Index
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. / Kerlikowske, Karla; Gard, Charlotte C.; Tice, Jeffrey A.; Ziv, Elad; Cummings, Steven R.; Miglioretti, Diana L.

In: Journal of the National Cancer Institute, Vol. 109, No. 5, djw276, 01.05.2017.

Research output: Contribution to journalArticle

Kerlikowske, Karla ; Gard, Charlotte C. ; Tice, Jeffrey A. ; Ziv, Elad ; Cummings, Steven R. ; Miglioretti, Diana L. / Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer. In: Journal of the National Cancer Institute. 2017 ; Vol. 109, No. 5.
@article{827c9e59009145a9ad16ca1c82c70ab9,
title = "Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer",
abstract = "Background: Risk factors may differentially influence development of estrogen receptor (ER)-positive vs -negative breast cancer. We examined associations with strong, prevalent risk factors by ER subtype. Methods: Of 1 279 443 women age 35 to 74 years participating in the Breast Cancer Surveillance Consortium, 14 969 developed ER-positive and 3617 developed ER-negative invasive breast cancer. We calculated hazard ratios (HRs) using Cox regression and compared ER subtype hazard ratios at representative ages or by menopausal status using Wald tests. All statistical tests were two-sided. Results: For women age 40 years, compared with no prior biopsy, ER-positive vs ER-negative HRs were 1.53 (95{\%} CI = 1.30 to 1.81) vs 1.26 (95{\%} CI = 0.90 to 1.76) for nonproliferative disease, 1.63 (95{\%} CI = 1.23 to 2.17) vs 1.41 (95{\%} CI = 0.78 to 2.57) for proliferative disease without atypia, and 4.47 (95{\%} CI = 2.88 to 6.96) vs 0.20 (95{\%} CI = 0.02 to 2.51) for proliferative disease with atypia. Benign disease proliferation risk was stronger for ER-positive than ER-negative cancer for women age 35 years (Wald P = .04), age 40 years (Wald P = .04), and age 50 years (Wald P = .06). Among pre/perimenopausal women, body mass index (BMI) had a stronger association with ER-negative than ER-positive cancer (obese II/III vs. normal weight: HR = 1.52, 95{\%} CI = 1.19 to 1.94; vs 1.21, 95{\%} CI = 1.08 to 1.36). Increasing BMI similarly increased ER-positive and ER-negative cancer risk among postmenopausal hormone users (Wald P = .15) and nonusers (Wald P = .08). Associations with ER subtype varied by race/ethnicity across all ages (P <. 001) and by family history of breast cancer and breast density for specific ages. Conclusions: Strength of risk factor associations differed by ER subtype. Separate risk models for ER subtypes may improve identification of women for targeted prevention strategies.",
author = "Karla Kerlikowske and Gard, {Charlotte C.} and Tice, {Jeffrey A.} and Elad Ziv and Cummings, {Steven R.} and Miglioretti, {Diana L}",
year = "2017",
month = "5",
day = "1",
doi = "10.1093/jnci/djw276",
language = "English (US)",
volume = "109",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer

AU - Kerlikowske, Karla

AU - Gard, Charlotte C.

AU - Tice, Jeffrey A.

AU - Ziv, Elad

AU - Cummings, Steven R.

AU - Miglioretti, Diana L

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Background: Risk factors may differentially influence development of estrogen receptor (ER)-positive vs -negative breast cancer. We examined associations with strong, prevalent risk factors by ER subtype. Methods: Of 1 279 443 women age 35 to 74 years participating in the Breast Cancer Surveillance Consortium, 14 969 developed ER-positive and 3617 developed ER-negative invasive breast cancer. We calculated hazard ratios (HRs) using Cox regression and compared ER subtype hazard ratios at representative ages or by menopausal status using Wald tests. All statistical tests were two-sided. Results: For women age 40 years, compared with no prior biopsy, ER-positive vs ER-negative HRs were 1.53 (95% CI = 1.30 to 1.81) vs 1.26 (95% CI = 0.90 to 1.76) for nonproliferative disease, 1.63 (95% CI = 1.23 to 2.17) vs 1.41 (95% CI = 0.78 to 2.57) for proliferative disease without atypia, and 4.47 (95% CI = 2.88 to 6.96) vs 0.20 (95% CI = 0.02 to 2.51) for proliferative disease with atypia. Benign disease proliferation risk was stronger for ER-positive than ER-negative cancer for women age 35 years (Wald P = .04), age 40 years (Wald P = .04), and age 50 years (Wald P = .06). Among pre/perimenopausal women, body mass index (BMI) had a stronger association with ER-negative than ER-positive cancer (obese II/III vs. normal weight: HR = 1.52, 95% CI = 1.19 to 1.94; vs 1.21, 95% CI = 1.08 to 1.36). Increasing BMI similarly increased ER-positive and ER-negative cancer risk among postmenopausal hormone users (Wald P = .15) and nonusers (Wald P = .08). Associations with ER subtype varied by race/ethnicity across all ages (P <. 001) and by family history of breast cancer and breast density for specific ages. Conclusions: Strength of risk factor associations differed by ER subtype. Separate risk models for ER subtypes may improve identification of women for targeted prevention strategies.

AB - Background: Risk factors may differentially influence development of estrogen receptor (ER)-positive vs -negative breast cancer. We examined associations with strong, prevalent risk factors by ER subtype. Methods: Of 1 279 443 women age 35 to 74 years participating in the Breast Cancer Surveillance Consortium, 14 969 developed ER-positive and 3617 developed ER-negative invasive breast cancer. We calculated hazard ratios (HRs) using Cox regression and compared ER subtype hazard ratios at representative ages or by menopausal status using Wald tests. All statistical tests were two-sided. Results: For women age 40 years, compared with no prior biopsy, ER-positive vs ER-negative HRs were 1.53 (95% CI = 1.30 to 1.81) vs 1.26 (95% CI = 0.90 to 1.76) for nonproliferative disease, 1.63 (95% CI = 1.23 to 2.17) vs 1.41 (95% CI = 0.78 to 2.57) for proliferative disease without atypia, and 4.47 (95% CI = 2.88 to 6.96) vs 0.20 (95% CI = 0.02 to 2.51) for proliferative disease with atypia. Benign disease proliferation risk was stronger for ER-positive than ER-negative cancer for women age 35 years (Wald P = .04), age 40 years (Wald P = .04), and age 50 years (Wald P = .06). Among pre/perimenopausal women, body mass index (BMI) had a stronger association with ER-negative than ER-positive cancer (obese II/III vs. normal weight: HR = 1.52, 95% CI = 1.19 to 1.94; vs 1.21, 95% CI = 1.08 to 1.36). Increasing BMI similarly increased ER-positive and ER-negative cancer risk among postmenopausal hormone users (Wald P = .15) and nonusers (Wald P = .08). Associations with ER subtype varied by race/ethnicity across all ages (P <. 001) and by family history of breast cancer and breast density for specific ages. Conclusions: Strength of risk factor associations differed by ER subtype. Separate risk models for ER subtypes may improve identification of women for targeted prevention strategies.

UR - http://www.scopus.com/inward/record.url?scp=85021361132&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021361132&partnerID=8YFLogxK

U2 - 10.1093/jnci/djw276

DO - 10.1093/jnci/djw276

M3 - Article

C2 - 28040694

AN - SCOPUS:85021361132

VL - 109

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 5

M1 - djw276

ER -